Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression

• Published in: Frontiers in immunology Vol. 11; p. 1191
• Main Authors: Alban, Tyler J., Bayik, Defne, Otvos, Balint, Rabljenovic, Anja, Leng, Lin, Jia-Shiun, Leu, Roversi, Gustavo, Lauko, Adam, Momin, Arbaz A., Mohammadi, Alireza M., Peereboom, David M., Ahluwalia, Manmeet S., Matsuda, Kazuko, Yun, Kyuson, Bucala, Richard, Vogelbaum, Michael A., Lathia, Justin D.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 18.06.2020
• Subjects: Animals; Brain Neoplasms - immunology; Glioblastoma - immunology; glioma; Humans; immunesuppresion; immunetherapy; Immunology; Immunotherapy - methods; Macrophage Migration-Inhibitory Factors - immunology; Macrophage Migration-Inhibitory Factors - metabolism; MDSC; Mice; MIF–macrophage migration inhibitory factor; Myeloid-Derived Suppressor Cells - immunology; Pyridines - pharmacology; Receptors, Immunologic - immunology; Receptors, Immunologic - metabolism; Tumor Escape - drug effects; Tumor Escape - immunology; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; glioma; immunetherapy; MDSC; immunesuppresion; MIF–macrophage migration inhibitory factor

The application of tumor immunotherapy to glioblastoma (GBM) is limited by an unprecedented degree of immune suppression due to factors that include high numbers of immune suppressive myeloid cells, the blood brain barrier, and T cell sequestration to the bone marrow. We previously identified an inc...